ICD 2025: New data demonstrate Nemluvio®'s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
Zug, Switzerland:
An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio was well tolerated and associated with sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, including both skin lesions and itch, up to two years 1
Results build on data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one assessing long-term safety and efficacy in prurigo nodularis 1-3
This follows the presentation of data from the ARCADIA long-term extension study at the Revolutionizing Atopic Dermatitis (RAD) Conference earlier this month, which showed Nemluvio is well tolerated with sustained and increased improvements in efficacy outcomes in atopic dermatitis patients up to two years4
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/
'These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it's highly encouraging to see its robust evidence base continue to expand and strengthen.'
BALDO SCASSELLATI SFORZOLINI, M.D., PHD.
GLOBAL HEAD OF RESEARCH & DEVELOPMENT
GALDERMA
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients' quality of life.5-7 Nemluviois the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31.8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis.8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment.9,10
The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials.1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years.1 At Week 100 in evaluable patients, the interim analysis shows that: More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale 1
At least 80% achieved 76‑100% healed pruriginous lesions 1
Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator's Global Assessment score1
Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date.1
'These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I'm thrilled to be able to see its meaningful impact in the real world.'
PROF. SONJA STÄNDER
LEAD INVESTIGATOR OF THE OLYMPIA STUDIES IN EUROPE
UNIVERSITY HOSPITAL MUNSTER, GERMANY
This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years.4
Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing.
Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea.
More details on Galderma's scientific presentations at ICD can be found here.
About Nemluvio
Nemluviowas initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.12,13
About prurigo nodularis
Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence.11,14,15
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy. ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025 ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025 Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States. Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183 Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570 Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042 Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013 Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025 Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025 Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2 Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025 Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025 Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009 Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-483.e4. doi: 10.1016/j.jid.2019.07.697
View source version on businesswire.com: https://www.businesswire.com/news/home/20250617336479/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Looking at ag mental health
Aug. 7—OLYMPIA — Improving mental health services for farmers and agricultural workers — and working to reduce the factors that lead to mental health challenges for them — are among the recommendations of a report issued by a Washington legislative task force working on the issue. Washington Rep. Tom Dent, R-Moses Lake, who worked to establish the task force, said what he learned caused him to revise some of his thinking. The task force examined two phases of the ag mental health issue, providing support tailored for the ag sector, and examining the contributing factors, what Dent called the upstream issues. When the task force started, he was focused on the need for additional mental health support, he said. "Now I'm more focused on going upstream," he said. One of the original goals of the report was to determine if the state's suicide hotlines could be made more accessible for farmers and farmworkers, including possibly a separate hotline for the agriculture sector. "That's what started the discussion," Dent said. The need for mental health support for ag professionals is statistically supported. The suicide rate for agricultural workers in Washington is 21.1 per 100,000. In comparison, the rate for the overall population is 14.9 per 100,000 Washingtonians, according to the Washington State Department of Agriculture, based on data from 2020 to 2022. One of the report recommendations is to add responders with knowledge of Washington agriculture to the hotline and include Spanish-speaking staff. Dent said that's a start, but it's not enough. "That's the Band-Aid," he said. As the task force kept working, Dent said he started to change his focus. "Maybe what's called for here — what I see is maybe we need to go back upstream," he said. The task force report includes a list of recommendations, both in terms of strengthening mental health support for farmers and farmworkers and reducing some of the challenges that contribute to stress in the ag sector. The report recommended full funding for an agriculture-based suicide hotline, along with additional support services. "Uncoordinated services should be reviewed for potential collaboration, particularly in addressing overlapping needs. There may also be value in developing follow-up teams with specialized roles, such as financial advisors and social workers, to support (hotline) callers more holistically," the report said. More work should be done to make people aware of the hotline and to reduce the stigma around asking for help with mental health challenges, it said. State Sen. Judy Warnick, R-Moses Lake, said the report highlighted some of the challenges faced by her own family when she was growing up. Her dad and uncle jointly operated a farm and kept their stresses to themselves, she said. "The more meetings we had to put together this report, the more I realized my dad and uncle were kind of typical," she said. The report suggests additional funding to help farmers and farm workers, along with the general public, learn more about the stresses that come with modern farming. More research is needed as well, the report said. There is a mental health support program for farmers and farmworkers operated through WSU-Skagit County Extension, and the report recommends expanding that. Warnick said that the program includes events for farmers and farmworkers designed to help make it easier for them to talk about some of their challenges and to be connected to mental health services. Among those events is "Pizza for Producers," one of which was held in Moses Lake, she said. Dent said that, in his opinion, the conditions causing stress for farmers and farmworkers need to be addressed. While farming is an attractive profession for the people who practice it, farmers and farm workers still need to be able to support themselves and their families, he said. "It's a labor of love — to a point," Dent said. "It's a lifestyle — to a point." The report recommends additional financial support, such as tax relief and no-interest loans, as possible options. State regulatory processes should be streamlined and improved, the report said, and there should be additional efforts to understand the challenges of farming and to treat farmers and farmworkers with respect. Many of the report's recommendations will require legislative action. Dent said he thinks there are opportunities. "There is a lot of interest in mental health in the legislature. There always has been," he said. Editor's Note: Anyone facing a mental health crisis and considering suicide is strongly encouraged to call or text 988, the National Suicide Crisis Hotline for assistance. Locally, HopeSource can direct those needing behavioral health services to the resources they need. Solve the daily Crossword
USA Today
5 days ago
- USA Today
Nashville General Hospital declines to disconnect inmate's heart device before execution
Hospital says it has no role in executions and that the state's account of its involvement is inaccurate. A local hospital where the state has been ordered to disconnect a death row inmate's heart device before his execution now says it never agreed to perform the procedure. Byron Black, 69, is set to be executed on Aug. 5 for the 1988 South Nashville murders of his ex-girlfriend Angela Clay and her two young daughters. His case is growing ever more complicated with his execution just days away. Black's lawyers have argued that his implantable cardioverter-defibrillator (ICD) for congestive heart failure would cause a prolonged and painful death by shocking him repeatedly as the lethal injection drug works its way through his system. A Davidson County Chancery Court judge in July ordered the state to disconnect the device on the morning of his execution at Nashville General Hospital. The state Attorney General's Office has pushed back on the order and is now appealing to the Tennessee Supreme Court. The state in court documents said a third-party provider would be willing to deactivate the device on Aug. 4 at Nashville General Hospital, as technicians would not come to the prison to perform the procedure. But Nashville General Hospital in a statement July 30 said reports of its involvement are inaccurate and that it has no role in executions. 'The correctional healthcare provider contracted by the Tennessee Department of Correction (TDOC), did not contact appropriate Nashville General Hospital leadership with its request to deactivate the implanted defibrillator,' Nashville General spokesperson Cathy Poole said in a statement. 'Any assertion the hospital would participate in the procedure was premature. Our contract with the correctional healthcare provider is to support the ongoing medical care of its patients." Poole said the request would require cooperation with 'several other entities, all of which have indicated they are unwilling to participate.' The debacle was first reported by WLPN news. TDOC deferred questions to the Tennessee Attorney General's Office. The office did not immediately respond to a request for comment. 'TDOC has mishandled this situation from the beginning,' Black's lawyer Kelley Henry, a supervisory assistant federal public defender, said in a statement. 'My hope is that the Governor will issue a reprieve to avoid a gruesome spectacle.' It's unclear what will now happen in his case. His execution is set to move forward unless a stay is issued by the U.S. Supreme Court or Gov. Bill Lee. Black filed a petition with the U.S. Supreme court on July 29 asking to stay his execution. His lawyers have noted that he is intellectually disabled and suffers from dementia, brain damage and heart failure. Under today's laws, he would not be eligible for execution.
Business Upturn
6 days ago
- Business Upturn
Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016
Business Wire India Polpharma Biologics S.A. ('Polpharma Biologics') announces a global (except for Middle East & North Africa) licensing agreement with Fresenius Kabi for the commercialization of PB016, a proposed biosimilar to vedolizumab, an integrin receptor antagonist, (reference product: Entyvio®*), a biologic therapy indicated for moderate to severe ulcerative colitis and Crohn's disease. Under the terms of the agreement, Polpharma Biologics will lead development and manufacturing of PB016, while Fresenius Kabi will hold exclusive commercialization rights worldwide, excluding Middle East & North Africa. 'This partnership reinforces our mission to broaden access to high-quality biologics that improve patient outcomes globally,' said Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group. 'Fresenius Kabi's deep commercialization experience and commitment to biosimilars make them an ideal partner for bringing PB016 to patients worldwide. Together, we are taking an important step toward addressing the rising burden of chronic inflammatory diseases.' The agreement builds on Polpharma Biologics' growing biosimilar portfolio and proven development capabilities. The company has previously brought forward multiple biosimilars — including ranibizumab and natalizumab — across global markets in partnership with leading pharmaceutical companies. This strategic collaboration strengthens both companies' commitments to expanding global access to affordable biologic medicines while supporting healthcare system sustainability. *Entyvio® is a registered trademark of Takeda. About Polpharma Biologics: Polpharma Biologics is an international biotechnology company with integrated operations in the European Union (EU), developing and manufacturing biosimilar medicines. Using patented solutions and state-of-the-art platform technologies, Polpharma Biologics develops biosimilar products to treat a range of conditions in major therapeutic areas. Programs at Polpharma Biologics start in cell line development and transition through technical and clinical development to commercial-scale production preparing drugs for future commercial partnerships with global pharmaceutical organizations. The expertise of Polpharma Biologics lies in the development and manufacture of medicines based on microbial and mammalian expression systems. With its cell line development center in the Netherlands and two centers of development and manufacturing in Poland, Polpharma Biologics creates growth and development opportunities for biotechnology specialists. Learn more at About Fresenius Kabi: As part of the global healthcare company Fresenius, Fresenius Kabi specializes in (bio)pharmaceuticals, medical technologies and nutrition products for critical and chronic conditions. The company's products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 41,000 employees and present in over 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. For more information, please visit Important Note This press release is for informational purposes only and does not constitute promotional material for PB016 in Poland or any other jurisdiction. The commercialization of proposed vedolizumab biosimilar PB016 is solely the responsibility of Fresenius Kabi, the marketing authorization holder, in accordance with all applicable laws and regulations. Disclaimer This press release is issued from Polpharma Biologics Group and is intended to provide worldwide information to healthcare professionals, media and (potential) investors about our global business in relation to drug development and manufacturing expertise. Although Polpharma Biologics Group is not a public company as of this date, recipients should understand that this press release contains certain forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). These statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the approval and commercialization of the medicinal product, market reception, competition, changes in economic conditions and applicable laws, global regulatory developments, contractual risks and dependencies from third parties. Polpharma Biologics undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release. Moreover, Polpharma Biologics wishes to emphasize that this press release is for informational purposes only and shall not be construed as making any representation, warranties, or guarantees, either express or implied, regarding the potential approval, market reception, commercialization, or success of the medicinal product or any other product or therapy. Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same. Ahmedabad Plane Crash
